The use of robotic tumor enucleation conferred favorable long-term surgical margins and local recurrence rates in patients with sporadic renal cell carcinoma (RCC), according to the results of a single-center Italian study.1 The findings were published online September 27, 2018, in Urologic Oncology. Patients undergoing robotic tumor enucleation with no ablation of the tumor bed…
Percutaneous microwave ablation (MWA) is a promising treatment strategy for patients with cT1-stage renal tumors, but more research into patient risk stratification and selection is needed.
Risk increased for papillary RCC but not clear-cell RCC; risk for upper tract urothelial carcinoma was also increased.
A review is presented of adverse events common with 5 oral chemotherapy drugs used to treat renal cell carcinoma.
An evaluation of patients with clear cell renal cell carcinoma revealed greater risk of death for female patients with high relative visceral fat area (rVFA), highlighting the significance of metabolic differences between men and women.
The employment of radical nephrectomy, vs partial nephrectomy, was found to cause a 2-fold greater decline in eGFR decline and greatly increased mortality.
Nonrandomized trial demonstrates tolerability and antitumor activity of a PD-1 checkpoint inhibitor plus a VEGF-TKI in patients with treatment-naïve advanced RCC.
Phase 3 study sought to assess the associations between adjuvant therapy with VEGF-tyrosine kinase inhibitors (TKIs) and benefit, sex, and age in patients with resected renal cell cancer.
Researchers evaluated the effect of antibiotics on treatment delays, interruptions, and dose reductions in patients with mRCC treated with a first-line VEGF-TKI and presented their results at the 2018 Genitourinary Cancers Symposium.
Combination therapy with lenvatinib and pembrolizumab is granted Breakthrough Therapy Designation for the treatment of advanced or metastatic renal cell carcinoma (RCC).
